Research Identifies Predictors For Successful IVF
(sz) Ferring Pharmaceuticals presented the results of a number of studies in assisted reproductive technology (ART) treatments at the 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in San Francisco, November 8-12, 2008. Four studies compared ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, to intramuscular (IM) progesterone-in-oil (PIO) for luteal support. Additional studies assessed the benefits of once-daily combined gonadotropin dosing compared with twice-daily dosing, and the safety and efficacy of MENOPUR(R) (menotropins for injection, USP) in polycystic ovarian syndrome (PCOS) patients.
“Four studies presented this year demonstrate that ENDOMETRIN has comparable efficacy and pregnancy rates to IM progesterone, and is a more patient-friendly, convenient form of administration,” said Paul Korner, MD, vice president, medical affairs, Ferring Pharmaceuticals, Inc. “Other studies presented provide the infertility community with clinically relevant information about physiological differences in treatment with human menopausal gonadotropin (hMG), which contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, compared with recombinant FSH only.” more…
From: »Medical News Today«